SecurAcath

Nurses and patients deal with a variety of risks and problems when catheters are secured with sutures. Jocelyn, RN, explains that the nurses in her practice expect and demand a SecurAcath device in any central line.

"We had a 25 - 30% dislodgement rate, which is too high. Bringing in an anchor, our displacement rate is less than 5%. When you go from 30% to 5, I see that as a success."

SecurAcath is "extremely beneficial" - hear more of Jocelyn's story and make the move to SecurAcath today! https://zurl.co/pKMO

SecurAcath clinician testimonial, Jocelyn Hill Clinical Nurse Specialist and Avanced Practice Nurse Jocelyn talks about the clinical benefits of SecurAcath for all types of vascular access catheters

DID YOU KNOW?

Device failure prior to therapy completion is common, estimated at 30% with dislodgement responsible for almost half of all failures.

A recent multi-centered randomized controlled trial published in Pediatrics has proven SecurAcath superior to adhesive securement device with significantly reduced catheter dislodgement rate.

Review the study: https://zurl.co/e6mT and contact us: https://zurl.co/rMLW to make the switch !

Securement to Prevent Noncuffed Central Venous Catheter Dislodgement in Pediatrics This superiority randomized clinical trial compares the rates of dislodgement for noncuffed central venous catheters secured with a subcutaneous anchor securement system with sutureless securement devices in pediatric patients.

A recent multi-centered randomized controlled trial published in Pediatrics providing the highest level of clinical evidence - found that SecurAcath (SASS) saves money every time it is used.

In this trial, evidence showed that SecurAcath provided a healthcare cost savings of AU $36.60 (approximately $24.36 USD) per patient, even with a relatively short dwell time of 25.5 days. This results in an annual cost savings of almost AU $20,000 based on approximately 520 nc-CVC insertions per year at a participating hospital.

Learn more about the study and the additional benefits of utilizing SecurAcath by reviewing the JAMA publication, here: https://zurl.co/9NAU

Securement to Prevent Noncuffed Central Venous Catheter Dislodgement in Pediatrics This superiority randomized clinical trial compares the rates of dislodgement for noncuffed central venous catheters secured with a subcutaneous anchor securement system with sutureless securement devices in pediatric patients.

"SecurAcath has been an absolute game changer, because now our catheters stay in for the entire duration of therapy. Our practice became, if you're going to put in a PICC line and it's going to be in for more than two dressing changes, you need a SecurAcath."

Linda S., RN a Vascular Access and Infusion Therapy Specialist from Florida , discovered SecurAcath at a conference and is no longer getting calls about patients pulling out their line. Learn more: https://zurl.co/NPDg

SecurAcath clinician testimonial Linda S Vascular Access Specialist, Linda S. talks about her success with SecurAcath

We’ll be at this September!

Join us September 28 – 30 in Denver, Colorado at the Ga***rd Rockies. Chat with the Eloquest Healthcare, Inc. team at Booth 311 and discover the many benefits of using SecurAcath .

Learn more: https://zurl.co/xntD

AVA 2024 Annual Scientific Meeting

A recent multi-centered randomized controlled trial published in JAMA Pediatrics providing the highest level of clinical evidence - found that SecurAcath (SASS) saves money every time it is used.

In this trial, evidence showed that SecurAcath provided a healthcare cost savings of AU $36.60 (approximately $24.36 USD) per patient, even with a relatively short dwell time of 25.5 days. This results in an annual cost savings of almost AU $20,000 based on approximately 520 nc-CVC insertions per year at a participating hospital.

Learn more about the study and the additional benefits of utilizing SecurAcath by reviewing the JAMA publication, here: https://zurl.co/9NAU

Securement to Prevent Noncuffed Central Venous Catheter Dislodgement in Pediatrics This superiority randomized clinical trial compares the rates of dislodgement for noncuffed central venous catheters secured with a subcutaneous anchor securement system with sutureless securement devices in pediatric patients.

Click to join! Starts in a few minutes!!

There's still time! 🌟 Register now for TODAY's AVA IV League Learning with "The Vascular Guy." Don’t miss out: https://bit.ly/3AoHJav
See you at 7:30pm ET!

A recent multi-centered randomized controlled trial published in JAMA Pediatrics providing the highest level of clinical evidence - found that SecurAcath (SASS) saves money every time it is used.

In this trial, evidence showed that SecurAcath provided a healthcare cost savings of AU $36.60 (approximately $24.36 USD) per patient, even with a relatively short dwell time of 25.5 days. This results in an annual cost savings of almost AU $20,000 based on approximately 520 nc-CVC insertions per year at a participating hospital.

Learn more about the study and the additional benefits of utilizing SecurAcath by reviewing the JAMA publication, here: https://zurl.co/9NAU

Securement to Prevent Noncuffed Central Venous Catheter Dislodgement in Pediatrics This superiority randomized clinical trial compares the rates of dislodgement for noncuffed central venous catheters secured with a subcutaneous anchor securement system with sutureless securement devices in pediatric patients.

We are excited to celebrate the success of our partners at Aberdeen Regional Hospital who have recently been recognized as a Nova Scotia Health Quality Award Winner for Excellence in Patient Safety!

The team initiated a 3-month trial using SecurAcath and found a 100% improvement with zero-line migrations and zero PICC line site infections!

Learn more about their trial and outcomes here: https://zurl.co/efzZ

SecurAcath 2024 NOVA SCOTIA HEALTH QUALITY AWARD WINNER Shawn and Melissa discuss the EXCELLENCE IN PATIENT SAFETY AWARD they received from Nova Scotia HealthRecognizes individuals/teams committed to improving pat...

Sorry, we will have to reschedule today's session! Look for an update in the next few days!